Related Experiment Video
Updated: Mar 2, 2026

In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption
Published on: June 20, 2017
Brain Perivascular Macrophages Initiate the Neurovascular Dysfunction of Alzheimer Aβ Peptides
Laibaik Park1, Ken Uekawa2, Lidia Garcia-Bonilla2
1From the Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, NY (L.P., K.U., L.G.B., K.K., M.M., P.Z., J.A., C.I.); McLaughlin Research Institute, Great Falls, MT (R.P., G.C.); and Mayo Clinic Jacksonville, FL (L.Y., S.Y.). lap2003@med.cornell.edu coi2001@med.cornell.edu.
Rationale:
Increasing evidence indicates that alterations of the cerebral microcirculation may play a role in Alzheimer disease, the leading cause of late-life dementia. The amyloid-β peptide (Aβ), a key pathogenic factor in Alzheimer disease, induces profound alterations in neurovascular regulation through the innate immunity receptor CD36 (cluster of differentiation 36), which, in turn, activates a Nox2-containing NADPH oxidase, leading to cerebrovascular oxidative stress. Brain perivascular macrophages (PVM) located in the perivascular space, a major site of brain Aβ collection and clearance, are juxtaposed to the wall of intracerebral resistance vessels and are a powerful source of reactive oxygen species.
Objective:
We tested the hypothesis that PVM are the main source of reactive oxygen species responsible for the cerebrovascular actions of Aβ and that CD36 and Nox2 in PVM are the molecular substrates of the effect.
Methods And Results:
Selective depletion of PVM using intracerebroventricular injection of clodronate abrogates the reactive oxygen species production and cerebrovascular dysfunction induced by Aβ applied directly to the cerebral cortex, administered intravascularly, or overproduced in the brain of transgenic mice expressing mutated forms of the amyloid precursor protein (Tg2576 mice). In addition, using bone marrow chimeras, we demonstrate that PVM are the cells expressing CD36 and Nox2 responsible for the dysfunction. Thus, deletion of CD36 or Nox2 from PVM abrogates the deleterious vascular effects of Aβ, whereas wild-type PVM reconstitute the vascular dysfunction in CD36-null mice.
Conclusions:
The data identify PVM as a previously unrecognized effector of the damaging neurovascular actions of Aβ and unveil a new mechanism by which brain-resident innate immune cells and their receptors may contribute to the pathobiology of Alzheimer disease.
Insights
Perivascular macrophages (PVMs) drive Alzheimer disease (AD) neurovascular dysfunction by producing reactive oxygen species. Targeting CD36 and Nox2 in PVMs may offer new therapeutic strategies for AD.
Area of Science:
- Neuroscience
- Immunology
- Vascular Biology
Background:
- Alzheimer disease (AD) involves cerebral microcirculation dysfunction.
- Amyloid-beta (Aβ) peptide triggers neurovascular changes via CD36 and Nox2, causing oxidative stress.
- Brain perivascular macrophages (PVMs) are key in Aβ clearance and produce reactive oxygen species.
Purpose of the Study:
- To determine if PVMs are the primary source of Aβ-induced reactive oxygen species.
- To investigate the role of CD36 and Nox2 in PVMs for Aβ's cerebrovascular effects.
Main Methods:
- Selective PVM depletion using clodronate.
- Aβ administration (direct cortical, intravascular) and transgenic mouse models (Tg2576).
- Bone marrow chimeras to assess cell-specific CD36/Nox2 roles.
Main Results:
- PVM depletion abolished Aβ-induced oxidative stress and vascular dysfunction.
- CD36 and Nox2 in PVMs are critical for Aβ's deleterious vascular effects.
- Deleting CD36 or Nox2 from PVMs prevented Aβ-induced dysfunction.
Conclusions:
- PVMs are a novel effector of Aβ's damaging neurovascular actions.
- Brain-resident innate immune cells and their receptors contribute to AD pathobiology.
- Identifies a new mechanism in Alzheimer disease pathogenesis involving PVMs.
More Related Videos
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
06:43A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
Published on: February 5, 2018
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...